BioSerenity, which develops data analytic tools through artificial intelligence (AI) to detect biomarkers for sleep disorders, is set to receive a €24m (approximately $26 million) investment from Jolt Capital, an independent private equity firm specializing in growth investments in European deeptech companies.
Founded in 2014, BioSerenity has designed a range of medical devices and software for electroencephalography. The company has also extended the scope of its solutions to other fields, including sleep disorders. BioSerenity is distributing its CE-marked, and US Food and Drug Administration-cleared cleared electroencephalogram monitoring hardware (Neuronaute and Icecap) as well as its AI-based diagnostic software (LR). BioSerenity has treated over 1 million patients since its foundation. Its solutions are protected by a portfolio of over 30 international patents.
Jolt Capital’s investment will enable the company to accelerate the international development of its activities by building on its two main markets, France and the United States, and focusing on Europe. BioSerenity will also use the funding to deploy even more powerful AI to help doctors with their diagnoses. The company’s management team also will be strengthened to drive BioSerenity’s development.
Jolt Capital’s portfolio also includes Alpha MOS, Interel, NIL Technology, Sinequa, and BC Platforms.